Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Cardiovasculares Carlos III (16)

2024

  1. Invasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 7, Núm. 3, pp. e240809

2023

  1. Case report: Alternative approach for management of refractory volume overload in heart failure: usefulness of venous leg compression

    Frontiers in Cardiovascular Medicine, Vol. 10

  2. Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

    Journal of Clinical Medicine, Vol. 12, Núm. 21

  3. Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial

    JAMA Internal Medicine, Vol. 183, Núm. 5, pp. 407-415

  4. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

2022

  1. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

  2. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2170-2180

  3. Serum potassium dynamics during acute heart failure hospitalization

    Clinical Research in Cardiology, Vol. 111, Núm. 4, pp. 368-379

  4. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2021

  1. Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

    Scientific Reports, Vol. 11, Núm. 1

  2. Mortality associated with cardiovascular disease in patients with COVID-19

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 30-38

  3. The pre-HFpEF stage: A new entity that requires proper phenotyping for better management

    European Journal of Preventive Cardiology

2020

  1. Estimation of the major cardiovascular events prevention with Inclisiran

    Atherosclerosis, Vol. 313, pp. 76-80

  2. Impact of pre-hospital renal function on the detection of acute kidney injury in acute decompensated heart failure

    European Journal of Internal Medicine, Vol. 77, pp. 66-72

2018

  1. Genetic Etiology for Alcohol-Induced Cardiac Toxicity

    Journal of the American College of Cardiology, Vol. 71, Núm. 20, pp. 2293-2302

2016

  1. Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study

    ESC Heart Failure, Vol. 3, Núm. 4, pp. 293-298